Acceler8 Limited, a venture builder based in Malta, has secured a further €350,000 in funding from the European Innovation Council (EIC) for its commercialisation of a new purification solution which is expected to lower the production cost of biopharmaceuticals.

As global demand for biological medicines grows in line with the need to address new therapeutic areas, the solution, termed BIOPURE, promises to lower manufacturing and purchase of equipment costs with a smaller footprint.

The end result is that citizens will have access to a more affordable and diverse selection of new generation biomedicines.

While already proven at laboratory scale, the solution is currently being further developed before being brought to market.

BIOPURE’s commercialisation plans are primarily targeted towards forming a startup that will manufacture and sell its equipment to biopharmaceutical laboratories and factories.

It claims that “a one-time, relatively low-cost investment has the potential of rendering annual savings amounting up to 15 times the cost of the investment.”

Acceler8 CEO Antti Heikkilä

The European Innovation Council’s funding, through its Transition 2022 programme, seeks to facilitate the maturation of novel technologies and their development of a business case.

“With the help of the EIC, we are able to strengthen our IP portfolio in the Life Sciences domain, and demonstrate the feasibility of the technology to potential clients and investors,” said Acceler8 CEO Antti Heikkilä.